Publications by authors named "R Cozzolongo"

Objective: This study aims to explore the association between liver steatosis and fibrosis, as assessed by Fibroscan, and the onset of type 2 diabetes in overweight, medication-free men and women.

Methods: We analyzed data from 164 participants with overweight or obesity (41.4 % male), including 39 individuals (23.

View Article and Find Full Text PDF

Treatment options for intrahepatic cholangiocarcinoma (iCCA), a highly malignant tumor with poor prognosis, are limited. Recent developments in immunotherapy and immune checkpoint inhibitors (ICIs) have offered new hope for treating iCCA. However, several issues remain, including the identification of reliable biomarkers of response to ICIs and immune-based combinations.

View Article and Find Full Text PDF

Management of severe thrombocytopenia poses significant challenges in patients with chronic liver disease. Here, we aimed to evaluate the first real-world European post-marketing cohort of cirrhotic patients treated with lusutrombopag, a thrombopoietin receptor agonist, verifying the efficacy and safety of the drug. In the REAl-world Lusutrombopag treatment in ITalY (REALITY) study, we collected data from consecutive cirrhotic patients treated with lusutrombopag in 19 Italian hepatology centers, mostly joined to the "Club Epatologi Ospedalieri" (CLEO).

View Article and Find Full Text PDF

Hepatitis E virus (HEV) infection is typically a self-limiting, acute illness that spreads through the gastrointestinal tract but replicates in the liver. However, chronic infections are possible in immunocompromised individuals. The HEV virion has two shapes: exosome-like membrane-associated quasi-enveloped virions (eHEV) found in circulating blood or in the supernatant of infected cell cultures and non-enveloped virions ("naked") found in infected hosts' feces and bile to mediate inter-host transmission.

View Article and Find Full Text PDF
Article Synopsis
  • Obesity and metabolic syndrome are closely associated with steatotic liver disease (SLD), which is the most common chronic liver disease, and lifestyle changes, especially a very low-calorie ketogenic diet (VLCKD), may help prevent this condition.
  • A study involving 112 overweight or obese participants examined the impacts of VLCKD on steatosis and fibrosis, revealing significant baseline differences between men and women regarding liver health, metabolic indicators, and body composition.
  • After the VLCKD intervention, both genders showed improvements in various health markers; however, men had initially higher levels of liver steatosis and fibrosis, and even after treatment, these gender-specific differences in liver health persisted.
View Article and Find Full Text PDF